Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts - PubMed (original) (raw)
. 1996 Jan-Feb;5(1):77-91.
doi: 10.1177/096368979600500113.
Affiliations
- PMID: 8665080
- DOI: 10.1177/096368979600500113
Free article
Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts
S W Robinson et al. Cell Transplant. 1996 Jan-Feb.
Free article
Abstract
The ability to replace damaged myocardial tissue with new striated muscle would constitute a major advance in the treatment of diseases that irreversibly injure cardiac muscle cells. The creation of focal grafts of skeletal muscle has been reported following the intramural injection of skeletal myoblasts into both normal and injured myocardium. The goals of this study were to determine whether skeletal myoblast-derived cells can be engrafted into the murine heart following arterial delivery. The murine heart was seeded with genetically labeled C2C12 myoblasts introduced into the arterial circulation of the heart via a transventricular injection. A transventricular injection provided access to the coronary and systemic circulations. Implanted cells were characterized using histochemical staining for beta-galactosidase, immunofluorescent staining for muscle-specific antigens, and electron microscopy. Initially the injected cells were observed entrapped in myocardial capillaries. One week after injection myoblasts were present in the myocardial interstitium and were largely absent from the myocardial capillary bed. Implanted cells underwent myogenic development, characterized by the expression of a fast-twitch skeletal muscle sarcoendoplasmic reticulum calcium ATPase (SERCA1) and formation of myofilaments. Four months following injection myoblast-derived cells began to express a slow-twitch/cardiac protein, phospholamban, that is normally not expressed by C2C12 cells in vitro. Most surprisingly, regions of close apposition between LacZ labeled cells and native cardiomyocytes contained structures that resembled desmosomes, fascia adherens junctions, and gap junctions. The cardiac gap junction protein, connexin43, was localized to some of the interfaces between implanted cells and cardiomyocytes. Collectively, these findings suggest that arterially delivered myoblasts can be engrafted into the heart, and that prolonged residence in the myocardium may alter the phenotype of these skeletal muscle-derived cells. Further studies are necessary to determine whether arterial delivery of skeletal myoblasts can be developed as treatment for myocardial dysfunction.
Similar articles
- Transmural replacement of myocardium after skeletal myoblast grafting into the heart. Too much of a good thing?
Reinecke H, Murry CE. Reinecke H, et al. Cardiovasc Pathol. 2000 Nov-Dec;9(6):337-44. doi: 10.1016/s1054-8807(00)00055-7. Cardiovasc Pathol. 2000. PMID: 11146303 - Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart.
Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Suzuki K, et al. Circulation. 2000 Nov 7;102(19 Suppl 3):III216-21. doi: 10.1161/01.cir.102.suppl_3.iii-216. Circulation. 2000. PMID: 11082390 - Gene transfer of connexin43 into skeletal muscle.
Reinecke H, Minami E, Virag JI, Murry CE. Reinecke H, et al. Hum Gene Ther. 2004 Jul;15(7):627-36. doi: 10.1089/1043034041361253. Hum Gene Ther. 2004. PMID: 15242523 - Muscle cell grafting for the treatment and prevention of heart failure.
Murry CE, Whitney ML, Reinecke H. Murry CE, et al. J Card Fail. 2002 Dec;8(6 Suppl):S532-41. doi: 10.1054/jcaf.2002.129268. J Card Fail. 2002. PMID: 12555170 Review. - Skeletal myoblasts as a therapeutic agent.
Menasché P. Menasché P. Prog Cardiovasc Dis. 2007 Jul-Aug;50(1):7-17. doi: 10.1016/j.pcad.2007.02.002. Prog Cardiovasc Dis. 2007. PMID: 17631434 Review.
Cited by
- Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure.
Taylor DA. Taylor DA. Curr Control Trials Cardiovasc Med. 2001;2(5):208-210. doi: 10.1186/cvm-2-5-208. Curr Control Trials Cardiovasc Med. 2001. PMID: 11806797 Free PMC article. - Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic.
Bockeria L, Bogin V, Bockeria O, Le T, Alekyan B, Woods EJ, Brown AA, Ichim TE, Patel AN. Bockeria L, et al. J Transl Med. 2013 Mar 5;11:56. doi: 10.1186/1479-5876-11-56. J Transl Med. 2013. PMID: 23510656 Free PMC article. Review. - Systems approaches to preventing transplanted cell death in cardiac repair.
Robey TE, Saiget MK, Reinecke H, Murry CE. Robey TE, et al. J Mol Cell Cardiol. 2008 Oct;45(4):567-81. doi: 10.1016/j.yjmcc.2008.03.009. Epub 2008 Mar 19. J Mol Cell Cardiol. 2008. PMID: 18466917 Free PMC article. Review. - Adult-derived stem cells from the liver become myocytes in the heart in vivo.
Malouf NN, Coleman WB, Grisham JW, Lininger RA, Madden VJ, Sproul M, Anderson PA. Malouf NN, et al. Am J Pathol. 2001 Jun;158(6):1929-35. doi: 10.1016/S0002-9440(10)64661-5. Am J Pathol. 2001. PMID: 11395367 Free PMC article. - Protein/polysaccharide-based scaffolds mimicking native extracellular matrix for cardiac tissue engineering applications.
Rosellini E, Zhang YS, Migliori B, Barbani N, Lazzeri L, Shin SR, Dokmeci MR, Cascone MG. Rosellini E, et al. J Biomed Mater Res A. 2018 Mar;106(3):769-781. doi: 10.1002/jbm.a.36272. Epub 2017 Nov 20. J Biomed Mater Res A. 2018. PMID: 29052369 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous